Related Experiment Video

Updated: Jun 23, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

C-Reactive protein gene variants are associated with postoperative C-reactive protein levels after coronary artery

Tjörvi E Perry1, Jochen D Muehlschlegel, Kuang-Yu Liu

  • 1Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. tjorviperry@gmail.com

BMC Medical Genetics
|May 12, 2009
PubMed

Insights

A specific C-reactive protein (CRP) gene variant, rs1800947, is linked to lower CRP levels after coronary artery bypass graft (CABG) surgery. This finding may impact understanding of cardiovascular disease risk and surgical inflammation.

Area of Science:

  • Genetics and Molecular Biology
  • Cardiovascular Disease Research
  • Surgical Inflammation

Background:

  • Elevated C-reactive protein (CRP) is a known cardiovascular disease risk factor.
  • CRP gene variants influence baseline CRP levels, but their role in surgical inflammation is unclear.
  • Investigating CRP gene variants in the context of coronary artery bypass graft (CABG) surgery is crucial.

Purpose of the Study:

  • To examine the association between candidate CRP gene variants and postoperative plasma CRP levels.
  • To understand the impact of CRP gene variants on CRP levels during the acute inflammatory response to CABG surgery with cardiopulmonary bypass (CPB).

Main Methods:

  • A multicenter candidate gene association study design was employed.
  • Seventeen candidate CRP single nucleotide polymorphisms (SNPs) and haplotypes were analyzed in 604 patients undergoing CABG surgery.
  • Perioperative CRP levels were measured at multiple time points: pre-surgery, post-CPB, and on postoperative days 1-4.

Main Results:

  • Postoperative CRP levels were significantly elevated compared to preoperative levels (P < 0.0001).
  • The minor allele of the synonymous coding SNP, rs1800947, was significantly associated with lower peak postoperative CRP levels (P = 2.4 x 10(-4)) and overall lower postoperative CRP levels (P = 4.8 x 10(-5)).
  • The association of rs1800947 with lower CRP levels remained significant after Bonferroni adjustment.

Conclusions:

  • A specific CRP gene SNP (rs1800947) is associated with reduced postoperative CRP levels in patients undergoing CABG surgery.
  • Further research is needed to elucidate the clinical significance of this CRP gene variant association.
  • Understanding this relationship may offer insights into adverse postoperative outcomes related to acute-phase CRP response.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...